Benzinga | Feb 25, 2021 04:49PM EST

Caladrius Biosciences Q4 EPS $(0.28) Misses $(0.25) Estimate

Caladrius Biosciences (NASDAQ:CLBS) reported quarterly losses of $(0.28) per share which missed the analyst consensus estimate of $(0.25) by 12 percent. This is a 40.43 percent increase over losses of $(0.47) per share from the same period last year.